查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830963

生物植入物市场

Bio-Implants Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

2024 年生物植入物市场价值为 1,275.9 亿美元，预计到 2031 年将达到 2,230.6 亿美元，2025 年至 2031 年的复合年增长率预计为 8.3%。

分析师观点：本报告概述了基于当前趋势和推动生物植入物市场发展的因素的成长机会。生物植入物市场扩张的主要因素包括慢性病发生率的上升（尤其是在老年人群体中），以及可支配收入的增加。已开发国家和发展中国家医疗基础设施的改善也有望显着推动生物植入物市场的发展。

在全球范围内，人们对美容植入物益处和技术进步的认识不断提高。生物植入物市场正在全球范围内增长，特别是由于牙科问题的日益普遍。此外，由于心血管和骨科疾病的发生率不断上升，对骨科植入物和心律调节器的需求也在上升。在北美，由于强大的医疗保健体系、人们对美容植入物认识的提高以及主要行业参与者的存在，生物植入物的销售量预计将增长。欧洲是全球第二大生物植入物市场，这得益于医疗保健技术的快速进步、对非侵入性生物植入物日益增长的需求以及老龄人口的不断增加。然而，生物植入手术的高成本以及对生物植入物产品合理使用的需求对市场成长构成了挑战。

市场概览：推动生物植入物市场成长的因素包括老年人骨质退化发生率的上升、对微创手术的需求不断增长以及生活方式相关疾病的激增。此外，预计医疗技术的进步将在未来几年显着影响生物植入物的市场前景。儘管医疗保健技术取得了显着进步，但严重疾病的发生率不断上升阻碍了生物植入物市场的发展。

策略洞察市场驱动力：生活方式障碍负担加重推动市场成长糖尿病、心血管疾病和骨关节炎等生活方式相关疾病在全球日益普遍，导致大量患者患病和死亡。生物植入物（包括支架和骨架）正在成为治疗这些疾病的传统永久性植入物的可行替代方案。根据美国心臟协会2021年的一篇文章，美国每年约有4万名儿童接受先天性心臟手术。英国心臟基金会发布的《2022年1月英国概况》报告称，2021年约有760万人患有心臟和循环系统疾病，其中近400万男性和360万女性受到影响。因此，心血管疾病盛行率的上升推动了对早期诊断和治疗的需求，预计这将增加对介入性心臟病学手术和心血管生物植入物的需求。此外，口腔健康问题的显着增加预计将增加对生物植入物的需求。世界卫生组织（WHO）2021年全球疾病负担研究显示，口腔疾病预计将影响全球近一半的人口，约35.8亿人受到龋齿和其他牙齿问题的影响。

此外，生物植入物在管理和输送针对肌肉骨骼疾病等疾病的特定药物方面发挥着至关重要的作用。 《骨科》杂誌2021年1月的一篇文章指出，北京中年族群腰椎滑脱的盛行率为17.26%（男性15.98%，女性18.80%），60岁以上的女性尤其容易罹患此病。世界卫生组织报告称，全球有17.1亿人患有肌肉骨骼损伤和疾病，是导致残疾的主要原因。 《柳叶刀风湿病学》发表的一项研究预测，到2050年，将有超过10亿人患有关节、肌肉、骨骼、韧带、肌腱和脊柱疾病，而2020年这一数字约为5亿。老年人口的增长导致患有肌肉骨骼疾病和相关功能障碍的人数迅速增加，导致对植入手术和住院治疗的需求增加，从而推动了生物植入物市场的发展。

分段分析：透过检查以下分段来分析生物植入物市场：类型、材料和最终用户。

按类型划分，生物植入物市场分为心血管植入物、骨科植入物、牙科植入物、眼科植入物及其他。心血管植入物领域在2023年占据了相当大的市场份额，这得益于旨在创造创新心臟植入产品的研发热潮。例如，2022年2月，医疗技术公司雅培宣布在其AVEIR DR i2i关键临床试验中，首次为患者植入了无导线双腔起搏器系统，标誌着无导线起搏器技术的重大技术进步。

生物植入物市场按材料分类，包括金属、陶瓷和聚合物。速释胶囊细分市场在 2023 年占据最大市场份额，预计在预测期内将呈现最高的复合年增长率。金属因其卓越的机械强度、耐腐蚀性和生物相容性而成为植入物的首选材料。钛因其卓越的耐用性、轻质特性以及与人体组织的相容性而被广泛用于骨科、牙科和心血管植入物。金属也因其延展性、导电性和惰性而受到特殊植入应用的重视，例如心臟电极和神经探针。慢性病的日益普及以及材料科学和製造技术的进步，正在推动生物植入物对生物材料金属的需求，巩固其作为生物植入物市场领先材料类别的地位。

按最终用户划分，市场分为医院和诊所以及门诊手术中心。 2023年，医院和诊所占据了生物植入物市场的较大份额，预计2023年至2031年期间的复合年增长率将更高。医院和诊所凭藉其全面的医疗项目和多学科的患者护理方法，吸引了大量患者，包括需要专门植入治疗的患者。医院经常与研究中心和医疗器材製造商合作，以获取尖端的植入技术。它们在生物植入物市场中发挥着至关重要的作用，提供必要的植入物相关服务，并对生物植入物产品和製程产生巨大的需求。因此，预计在预测期内，医院和诊所数量的增加，加上医疗保健需求的不断增长，将支持该细分市场的成长。

区域分析：生物植入物市场报告涵盖北美、欧洲、亚太地区、中东和非洲以及南美和中美。 2023 年北美市场价值为 505.1 亿美元，预计到 2031 年将达到 966.9 亿美元，2023 年至 2031 年的复合年增长率为 8.5%。北美市场分为美国、加拿大和墨西哥，成长归因于慢性病盛行率的上升和医疗基础设施的改善。美国疾病管制与预防中心 (CDC) 2022 年 7 月的最新资料表明，冠状动脉疾病是最常见的心臟病之一，影响美国约 2,010 万名 20 岁及以上的成年人。此外，CDC资料显示，每 40 秒就会发生一次心臟病，影响近 805,000 人。预计预测期内慢性病发生率的增加将推动对生物植入物的整体需求。

根据医疗保险和医疗补助服务中心的数据，到 2028 年，全国医疗保健支出预计将达到 6.2 兆美元，2019 年至 2028 年的年均成长率为 5.4%。由于全国医疗保健支出预计将增加 1.1 个百分点，预计到 2028 年医疗保健产业在经济中的份额将上升到 19.7%，超过 2019 年至 2028 年的年均 GDP 成长率。因此，预计不断增长的医疗保健支出将为市场参与者在预测期内开发生物植入物创造机会。

2023年，欧洲占据生物植入物市场第二大份额，其成长得益于医疗保健技术的进步、非手术生物植入物需求的增长以及老龄化人口的增长。欧洲市场的成长得益于政府资金和医疗保健计划、骨科疾病发病率的上升以及医疗保健领域研发活动的增加。此外，由于该地区心血管疾病发生率的上升，心血管手术数量的增加也推动了生物植入物市场的发展。

预计从 2023 年到 2031 年，亚太地区将成为全球生物植入物市场中复合年增长率最高的地区。该地区市场的成长得益于老龄人口的增加、可支配收入的提高、医疗保健投资的增加、市场参与者的扩张，以及交通事故导致的脊髓损伤的增加。亚太地区正在经历显着的成长，尤其是在中国和印度等新兴市场。医疗保健基础设施的扩建和为改善患者服务而增加的该领域投资，正在推动该地区生物植入物市场的发展。例如，日本庆应义塾大学 2019 年的出版品报道称，日本约有 10 万名患者因脊髓损伤而瘫痪。然而，iPS 技术的批准预计将在不久的将来帮助这些患者，从而可能为生物植入物市场创造机会。根据联合国亚洲经济社会委员会和太平洋社会发展部统计，2016年亚洲60岁以上人口占总人口的12.4%以上，预计2050年将达到13亿人。

生物植入物市场报告范围关键参与者分析：生物植入物市场报告中介绍的关键参与者包括 LifeNet Health、Smith & Nephew、Arthrex, Inc.、Clinic Lemanic、Alpha Bio Tec、MiMedx Group、Medtronic、St Jude Medical (Abbott)、Stryker Corporation、DePuy Synthes、Biomet, Inc.、Exacm、Exac)、Exacronxs Syn

最新动态：市场上的公司正在进行併购。以下是根据公司新闻稿得出的一些最新关键动态：

2023 年 2 月，专注于修復弯曲骨骼骨折的医疗器材开发商 CurvaFix, Inc. 推出了直径较小的 7.5 毫米 CurvaFix IM 植入物，旨在简化手术程序并在小骨骼中提供牢固、稳定的固定。 2022 年 6 月，ZimVie 在美国推出了经 FDA 批准的 T3 专业工程植入物和 Encode Emergence 癒合基台。 2021 年 6 月，Intelligent Implants Ltd. 的 SmartFuse 获得美国 FDA 的突破性认证，这是一项骨科植入物技术，旨在远端刺激、控制和监测骨骼生长，以便即时进行临床决策，适用于首次使用腰椎融合术的患者。 2021 年 2 月，美敦力推出了 TYRX 可吸收抗菌鞘，这是一款可吸收的一次性抗菌鞘，旨在稳定心臟植入式电子设备或植入式神经刺激器。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：生物植入物市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：生物植入物市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：生物植入物市场－全球市场分析

  • 生物植入物 - 全球市场概览
  • 生物植入物－全球市场及2031年预测

第七章：生物植入物市场-收入分析-按类型，2021-2031

  • 概述
  • 心血管植入物
  • 脊椎植入物
  • 骨科植入物
  • 牙种植体
  • 眼科植入物
  • 其他的

第 8 章：生物植入物市场 - 收入分析 - 依材料，2021-2031 年

  • 概述
  • 金属
  • 陶瓷
  • 聚合物

第九章：生物植入物市场-收入分析-按最终用户，2021-2031

  • 概述
  • 医院和诊所
  • 门诊手术中心

第 10 章：生物植入物市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 11 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 12 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 13 章：生物植入物市场 - 主要公司简介

  • LifeNet Health
  • Smith & Nephew
  • Arthrex, Inc.
  • Clinic Lemanic
  • Alpha Bio Tec
  • MiMedx Group
  • Medtronic
  • St Jude Medical (Abbott)
  • Stryker Cooperation
  • DePuy Synthes
  • Biomet (Zimmer)
  • Exactech, Inc.
  • Cochlear Ltd
  • Straumann AG

第 14 章：附录

简介目录
Product Code: TIPHE100001101

The bio-implants market was valued at US$ 127.59 billion in 2024 and is anticipated to reach US$ 223.06 billion by 2031, with an estimated CAGR of 8.3% from 2025 to 2031.

Analyst Perspective:This report outlines growth opportunities based on current trends and factors driving the bio-implants market. Key contributors to the expanding bio-implants market include the rising incidence of chronic diseases, especially among the elderly, and increasing disposable incomes. The enhancement of healthcare infrastructure in both developed and developing nations is also expected to significantly boost the bio-implants market.

Global awareness regarding the benefits of cosmetic implants and advancements in technology has risen. The bio-implants market is experiencing growth worldwide, particularly due to the increasing prevalence of dental issues. Additionally, the demand for orthopedic implants and pacemakers is on the rise due to the growing incidence of cardiovascular and orthopedic conditions. In North America, sales of bio-implants are projected to increase, driven by a strong healthcare system, heightened awareness of cosmetic implants, and the presence of major industry players. Europe ranks as the second-largest bio-implants market globally, fueled by rapid technological progress in healthcare, a growing demand for non-invasive bio-implants, and an increasing elderly population. However, the high costs associated with bio-implant procedures and the need for proper utilization of bio-implant products pose challenges to market growth.

Market Overview:Factors driving the growth of the bio-implants market include the rising incidence of bone degeneration in older adults, an increasing demand for minimally invasive surgical options, and a surge in lifestyle-related disorders. Furthermore, advancements in healthcare technology are expected to significantly influence the bio-implants market outlook in the coming years. Despite notable technological progress in healthcare, the rising prevalence of serious medical conditions has impeded the bio-implants market.

Strategic Insights Market Driver: Increasing Burden of Lifestyle Disorders Propel Market Growth

Lifestyle-related disorders such as diabetes, cardiovascular diseases, and osteoarthritis are becoming more common globally, leading to significant morbidity and mortality. Bio-implants, including stents and scaffolds, are emerging as viable alternatives to traditional permanent implants for treating these conditions. According to a 2021 article from the American Heart Association, approximately 40,000 children in the US undergo congenital heart surgery annually. The "UK Factsheet January 2022" from the British Heart Foundation reported that around 7.6 million individuals live with heart and circulatory diseases, with nearly 4 million men and 3.6 million women affected in 2021. Consequently, the rising prevalence of cardiovascular diseases is driving the demand for early diagnosis and treatment, which is expected to boost the need for interventional cardiology procedures and cardiovascular bio-implants. Additionally, a significant increase in oral health issues is anticipated to elevate the demand for bio-implants. The World Health Organization (WHO) 2021 Global Burden of Disease Study indicated that oral diseases are projected to impact nearly half of the global population, with approximately 3.58 billion individuals affected by dental caries and other dental issues.

Moreover, bio-implants play a crucial role in managing and delivering specific medications for conditions like musculoskeletal disorders. A January 2021 article in Orthopedic Surgery noted that the prevalence of lumbar spondylolisthesis among middle-aged individuals in Beijing was 17.26% (15.98% in men and 18.80% in women), with women over 60 being particularly susceptible. The WHO reports that musculoskeletal injuries and diseases affect 1.71 billion people globally, making them a leading cause of disability. Projections suggest that by 2050, over 1 billion individuals will suffer from joint, muscle, bone, ligament, tendon, and spine diseases, up from about half a billion in 2020, according to a study published in The Lancet Rheumatology. The growing elderly population is rapidly increasing the number of individuals with musculoskeletal conditions and related functional limitations, leading to a higher demand for implant procedures and hospitalizations, thus propelling the bio-implants market.

Segmental Analysis:The analysis of the bio-implants market has been conducted by examining the following segments: type, material, and end user.

By type, the bio-implants market is categorized into cardiovascular implants, orthopedic implants, dental implants, ophthalmic implants, and others. The cardiovascular implants segment accounted for a significant market share in 2023, driven by a surge in research and development aimed at creating innovative cardiac implant products. For instance, in February 2022, Abbott, a medical technology firm, announced the first patient implantation of a leadless dual-chamber pacemaker system as part of its AVEIR DR i2i pivotal clinical trial, marking a significant technological advancement in leadless pacemaker technology.

The bio-implants market, categorized by material, includes metals, ceramics, and polymers. The immediate-release capsules segment held the largest market share in 2023 and is expected to exhibit the highest CAGR during the forecast period. Metals are preferred for implant applications due to their exceptional mechanical strength, corrosion resistance, and biocompatibility. Titanium is a widely used material for orthopedic, dental, and cardiovascular implants due to its remarkable durability, lightweight nature, and compatibility with human tissue. Metals are also valued for specialized implant applications such as cardiac electrodes and neurological probes due to their malleability, electrical conductivity, and inertness. The increasing prevalence of chronic diseases and advancements in materials science and manufacturing techniques are driving the demand for biomaterial metals in bio-implants, solidifying their position as the leading material category in the bio-implants market.

By end user, the market is divided into hospitals & clinics and ambulatory surgical centers. The hospitals & clinics segment held a larger share of the bio-implants market in 2023 and is projected to register a higher CAGR from 2023 to 2031. Hospitals & clinics attract a large patient base, including those requiring specialized implant treatments, due to their comprehensive medical programs and multidisciplinary approach to patient care. Hospitals often collaborate with research centers and medical device manufacturers to access cutting-edge implant technologies. They play a crucial role in the bio-implants market by providing essential implant-related services and generating significant demand for bio-implant products and processes. Thus, the increasing number of hospitals & clinics, coupled with the rising demand for medical care, is expected to support the growth of this segment during the forecast period.

Regional Analysis:The bio-implants market report encompasses North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. The North American market was valued at US$ 50.51 billion in 2023 and is projected to reach US$ 96.69 billion by 2031, with an expected CAGR of 8.5% from 2023 to 2031. The market in North America is segmented into the US, Canada, and Mexico, with growth attributed to the rising prevalence of chronic diseases and improved healthcare infrastructure. Updated data from the Centers for Disease Control and Prevention (CDC) in July 2022 indicates that coronary artery disease is one of the most prevalent heart diseases, affecting approximately 20.1 million adults aged 20 and older in the US. Additionally, CDC data reveals that a heart attack occurs every 40 seconds, affecting nearly 805,000 individuals. The increasing incidence of chronic diseases is expected to drive the overall demand for bio-implants during the forecast period.

According to the Centers for Medicare and Medicaid Services, national healthcare spending is projected to reach US$ 6.2 trillion by 2028, growing at an average annual rate of 5.4% from 2019 to 2028. As national healthcare spending is expected to increase by 1.1 percentage points, the healthcare sector's share of the economy is anticipated to rise to 19.7% by 2028, outpacing the average annual GDP growth from 2019 to 2028. Consequently, the rising healthcare expenditure is expected to create opportunities for market players to develop bio-implants during the forecast period.

Europe holds the second-largest share of the bio-implants market in 2023, with growth attributed to technological advancements in healthcare, increased demand for non-surgical bio-implants, and a growing elderly population. The market growth in Europe is supported by government funding and healthcare initiatives, a rising incidence of orthopedic diseases, and increased research and development activities in healthcare. Furthermore, the growing number of cardiovascular surgeries due to the rising incidence of cardiovascular diseases in the region is driving the bio-implants market.

Asia Pacific is expected to exhibit the highest CAGR in the global bio-implants market from 2023 to 2031. The market growth in this region is driven by the increasing elderly population, rising disposable incomes, growing healthcare investments, and the expansion of market players, along with a rise in spinal cord injuries due to traffic accidents. Asia Pacific is experiencing significant growth, particularly in emerging markets like China and India. The expansion of healthcare infrastructure and increased investments in this sector to enhance patient services are propelling the bio-implants market in the region. For instance, a 2019 publication from Japan's Keio University reported that approximately 100,000 patients in Japan are paralyzed due to spinal cord injuries. However, the approval of iPS technology is expected to assist these patients in the near future, potentially creating opportunities in the bio-implants market. According to the United Nations Economic and Social Commission for Asia and the Department of Social Development in the Pacific, in 2016, over 12.4% of Asia's population was over 60 years old, a figure projected to reach 1.3 billion by 2050.

Bio-implants Market Report Scope Key Player Analysis:Key players profiled in the bio-implants market report include LifeNet Health, Smith & Nephew, Arthrex, Inc., Clinic Lemanic, Alpha Bio Tec, MiMedx Group, Medtronic, St Jude Medical (Abbott), Stryker Corporation, DePuy Synthes, Biomet (Zimmer), Exactech, Inc., Cochlear Ltd, and Straumann AG.

Recent Developments:Companies in the market are engaging in mergers and acquisitions. Below are some recent key developments based on company press releases:

In February 2023, CurvaFix, Inc., a medical device developer focused on repairing fractures in curved bones, launched its smaller diameter 7.5mm CurvaFix IM implant, designed to simplify surgical procedures and provide strong, stable fixation in small bones.In June 2022, ZimVie introduced the FDA-approved T3 pro-engineered implants and Encode Emergence Healing Abutment in the US.

In June 2021, Intelligent Implants Ltd. received breakthrough designation from the US FDA for SmartFuse, an orthopedic implant technology designed to remotely stimulate, control, and monitor bone growth for real-time clinical decisions, indicated for first-use patients undergoing lumbar spinal fusion.

In February 2021, Medtronic launched the TYRX Absorbable Antibacterial Sheath, an absorbable, disposable antibacterial sheath designed for stabilizing a cardiac implantable electronic device or implanted neurostimulator.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Bio Implants Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Bio Implants Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Bio Implants Market - Global Market Analysis

  • 6.1 Bio Implants - Global Market Overview
  • 6.2 Bio Implants - Global Market and Forecast to 2031

7. Bio Implants Market - Revenue Analysis (USD Million) - By Type, 2021-2031

  • 7.1 Overview
  • 7.2 Cardiovascular Implants
  • 7.3 Spinal Implants
  • 7.4 Orthopedics Implants
  • 7.5 Dental Implants
  • 7.6 Ophthalmic Implants
  • 7.7 Others

8. Bio Implants Market - Revenue Analysis (USD Million) - By Material, 2021-2031

  • 8.1 Overview
  • 8.2 Metal
  • 8.3 Ceramics
  • 8.4 Polymers

9. Bio Implants Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 9.1 Overview
  • 9.2 Hospitals and Clinics
  • 9.3 Ambulatory Surgical Centers

10. Bio Implants Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Bio Implants Market Overview
    • 10.1.2 North America Bio Implants Market Revenue and Forecasts to 2031
    • 10.1.3 North America Bio Implants Market Revenue and Forecasts and Analysis - By Type
    • 10.1.4 North America Bio Implants Market Revenue and Forecasts and Analysis - By Material
    • 10.1.5 North America Bio Implants Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Bio Implants Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Bio Implants Market
        • 10.1.6.1.1 United States Bio Implants Market, by Type
        • 10.1.6.1.2 United States Bio Implants Market, by Material
        • 10.1.6.1.3 United States Bio Implants Market, by End User
      • 10.1.6.2 Canada Bio Implants Market
        • 10.1.6.2.1 Canada Bio Implants Market, by Type
        • 10.1.6.2.2 Canada Bio Implants Market, by Material
        • 10.1.6.2.3 Canada Bio Implants Market, by End User
      • 10.1.6.3 Mexico Bio Implants Market
        • 10.1.6.3.1 Mexico Bio Implants Market, by Type
        • 10.1.6.3.2 Mexico Bio Implants Market, by Material
        • 10.1.6.3.3 Mexico Bio Implants Market, by End User
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 U.A.E
    • 10.4.4 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Industry Landscape

  • 11.1 Mergers and Acquisitions
  • 11.2 Agreements, Collaborations, Joint Ventures
  • 11.3 New Product Launches
  • 11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

  • 12.1 Heat Map Analysis by Key Players
  • 12.2 Company Positioning and Concentration

13. Bio Implants Market - Key Company Profiles

  • 13.1 LifeNet Health
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Smith & Nephew
  • 13.3 Arthrex, Inc.
  • 13.4 Clinic Lemanic
  • 13.5 Alpha Bio Tec
  • 13.6 MiMedx Group
  • 13.7 Medtronic
  • 13.8 St Jude Medical (Abbott)
  • 13.9 Stryker Cooperation
  • 13.10 DePuy Synthes
  • 13.11 Biomet (Zimmer)
  • 13.12 Exactech, Inc.
  • 13.13 Cochlear Ltd
  • 13.14 Straumann AG

14. Appendix

  • 14.1 Glossary
  • 14.2 About The Insight Partners
  • 14.3 Market Intelligence Cloud